🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

624 results for “Solid” Clear

  1. IPN60300

    Ipsen Pharma

    Advanced or metastatic solid tumours

    phase 2 small molecule active

    1 trial

  2. IRINOTECAN, lurbinectedin

    Pharma Mar S.A.

    Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  3. Iclusig 15 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Ponatinib, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 30 mg film-coated tablets., Ponatinib, Iclusig 45 mg film-coated tablets, Ponatinib

    Incyte Biosciences Distribution B.V.

    Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors

    phase 2 small molecule active

    1 trial

  4. Ifetroban Sodium

    CUMBERLAND PHARMACEUTICALS INC

    Malignant Solid Tumor

    phase 2 small molecule active

    1 trial

  5. Ifinatamab deruxtecan

    Daiichi Sankyo Europe GmbH

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  6. Imx-110

    Immix Biopharma

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  7. JAB-21822

    Pharma Mar S.A.

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  8. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  9. JNJ-42756493, JNJ-42756493, JNJ-42756493

    Janssen-Cilag International N.V.

    Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

    phase 2 small molecule active

    1 trial

  10. JNJ-73841937, PEMETREXED , JNJ-61186372, CARBOPLATIN

    Janssen-Cilag International N.V.

    Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  11. JZP598

    Jazz Pharmaceuticals Ireland Limited

    Patients with HER2-expressing solid tumors

    phase 2 small molecule active

    1 trial

  12. JZP598

    Cancer Prevention Pharma (Ireland) Limited

    Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, colorectal, head & neck or sarcoma) or HER2 mutant non-small cell lung cancer.

    phase 2 small molecule active

    1 trial

  13. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  14. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Acasunlimab

    Genmab A/S

    Malignant Solid Tumors - Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CETUXIMAB, olomorasib

    Eli Lilly Co.

    KRAS G12C-Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  16. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MDNA11

    Medicenna Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  17. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PRT3789

    Prelude Therapeutics Inc

    non-small cell lung cancer (NSCLC), Esophageal Cancer, Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    phase 2 small molecule active

    1 trial

  18. LB101

    Centessa Pharmaceuticals plc

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  19. LB1410

    China SXT Pharmaceuticals

    Solid Tumor

    phase 2 small molecule active

    1 trial

  20. LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB

    Novartis Ophthalmics Europe

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  21. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Ophthalmics Europe

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  22. LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., REGN10597

    Pharma Mar S.A.

    Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  23. LUMYKRAS 120 mg film-coated tablets, LUMYKRAS 240 mg film-coated tablets

    Pharma Mar S.A.

    Non-Small Cell Lung Cancer, Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  24. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources